Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

RZLT

Rezolute Inc

Oct 15 • 04:00PM ET

4.82

Dollar change +0.04
Percentage change 0.84	%

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX MACA RKDA

| Held by: VTI VXF IWC AVSC DFAC DFAT DFAS RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	16.67%	Shs Outstand	53.25M	Perf Week	0.84%
Market Cap	269.58M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	0.73%	Shs Float	46.60M	Perf Month	-6.41%
Income	-68.46M	PEG	-	EPS next Q	-0.32	Inst Own	65.97%	Short Float	2.31%	Perf Quarter	3.88%
Sales	0.00M	P/S	-	EPS this Y	6.87%	Inst Trans	56.72%	Short Ratio	3.38	Perf Half Y	41.76%
Book/sh	2.27	P/B	2.12	EPS next Y	-6.57%	ROA	-53.39%	Short Interest	1.08M	Perf Year	456.97%
Cash/sh	2.27	P/C	2.12	EPS next 5Y	-	ROE	-57.73%	52W Range	0.72 - 6.10	Perf YTD	385.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	40.87%	ROI	-55.81%	52W High	-20.98%	Beta	1.20
Dividend TTM	-	Quick Ratio	13.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	569.44%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	13.39	EPS Y/Y TTM	-31.44%	Oper. Margin	0.00%	RSI (14)	51.20	Volatility	3.77% 5.91%
Employees	59	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.25	Target Price	12.75
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-77.67%	Payout	-	Rel Volume	0.49	Prev Close	4.78
Sales Surprise	-	EPS Surprise	-38.58%	Sales Q/Q	-	Earnings	Sep 19 AMC	Avg Volume	318.74K	Price	4.82
SMA20	0.14%	SMA50	2.81%	SMA200	48.20%	Trades		Volume	156,048	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
08:00AM	Loading…
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Loading…
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
07:00AM	Loading…
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)
09:33AM	Rezolute, Inc. Announces Closing of Registered Direct Offering (GlobeNewswire)
May-01-22 11:25PM	Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (GlobeNewswire)
02:00PM	Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism (GlobeNewswire)
Apr-26-22 04:05PM	RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 (GlobeNewswire) -7.74% +5.06%
Mar-29-22 07:00AM	Rezolute Joins the Rare Disease Company Coalition (GlobeNewswire) -8.72%
Mar-23-22 07:00AM	Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +7.34%
Feb-22-22 07:00AM	Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME (GlobeNewswire) -6.18%
Feb-09-22 04:05PM	Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
Nov-12-21 04:05PM	Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? (Simply Wall St.)
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering (GlobeNewswire) -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering (GlobeNewswire)
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 (GlobeNewswire)
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -8.69%
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism (GlobeNewswire) +7.00%
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME (GlobeNewswire) +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index (GlobeNewswire)
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead (TipRanks) +25.12%
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? (Simply Wall St.)
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential (TipRanks)
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs (GlobeNewswire)
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board (GlobeNewswire)
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit (GlobeNewswire)
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema (GlobeNewswire)
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners (GlobeNewswire)
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 (GlobeNewswire)
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts (GlobeNewswire) +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March (GlobeNewswire) -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results (GlobeNewswire) -9.07% +5.51%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema (GlobeNewswire) +6.84%
Jan-11-21 07:56AM	What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)? (Simply Wall St.) -6.15%
Dec-28-20 04:05PM	Rezolute Announces Change of Transfer Agent (GlobeNewswire) -11.97%
Dec-03-20 08:00AM	FDA Clears Rezolutes IND Application for RZ402 (GlobeNewswire) +7.64%
Nov-19-20 08:00AM	Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-05-20 08:00AM	Rezolute Announces Uplisting to the Nasdaq Capital Market (GlobeNewswire) +11.11%
Oct-09-20 08:30AM	Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq (GlobeNewswire) +8.75%
Sep-10-20 08:00AM	Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors (GlobeNewswire)
Jul-27-20 08:00AM	Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism (GlobeNewswire)
Jun-15-20 08:30AM	Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science (GlobeNewswire) -10.58%
May-28-20 08:30AM	Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hogenhuis Wladimir	Director	Sep 24 '24	Buy	4.70	4,259	20,017	41,767	Sep 24 05:14 PM
Hogenhuis Wladimir	Director	Jun 25 '24	Buy	4.15	4,815	19,982	37,508	Jun 27 02:00 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	4,300	16,828	54,352	Jun 14 12:51 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	3,300	12,916	13,000	Jun 14 12:51 PM
Evans Daron	CFO	Jun 14 '24	Buy	4.04	40,000	161,568	40,000	Jun 14 12:06 PM
Evans Daron	CFO	May 29 '24	Buy	3.50	451	1,578	121,351	May 31 04:05 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	May 23 '24	Buy	2.69	7,500	20,138	50,052	May 28 02:56 PM
Evans Daron	CFO	May 24 '24	Buy	3.23	2,942	9,503	13,000	May 28 02:48 PM
Evans Daron	CFO	May 23 '24	Buy	2.85	58	165	10,058	May 28 02:48 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 28 '24	Buy	2.55	500	1,275	1,076	Mar 29 11:08 AM
Evans Daron	CFO	Mar 15 '24	Buy	1.69	20,000	33,830	20,000	Mar 19 09:17 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 14 '24	Buy	1.88	10,000	18,800	10,000	Mar 18 11:20 AM
Kim Young-Jin	Director	Mar 07 '24	Buy	1.91	36,503	69,859	115,450	Mar 14 10:35 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 07 '24	Buy	1.85	500	925	500	Mar 11 10:35 AM
Evans Daron	CFO	Mar 08 '24	Buy	1.93	50,000	96,345	120,900	Mar 08 12:37 PM
Elam Nevan C	CEO	Feb 26 '24	Buy	1.68	5,000	8,400	7,817	Feb 28 11:40 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 23 '24	Buy	1.69	6,000	10,140	40,552	Feb 27 08:47 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 26 '24	Buy	1.70	2,000	3,400	42,552	Feb 27 08:47 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 16 '24	Buy	1.31	7,000	9,142	34,552	Feb 21 11:55 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.30	41,900	54,411	70,900	Feb 20 07:01 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.37	9,000	12,330	4,500	Feb 20 07:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RZLT

Rezolute Inc

Upgrade your FINVIZ experience